After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
RARE belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Ultragenyx Pharmaceutical Inc is $2.61B. A total of 2.03 million shares were traded on the day, compared to an average of 1.68M shares.
In the most recent transaction, Sanders Corazon (Corsee) D. sold 2,405 shares of RARE for 37.39 per share on Jun 20 ’25. After the transaction, the Director now owns 15,344 company shares. In a previous transaction on Jun 20 ’25, CORAZON D. SANDERS bought 2,405 shares at 37.39 per share.
Among the insiders who sold shares, Crombez Eric disposed of 520 shares on May 05 ’25 at a per-share price of $39.24. This resulted in the EVP and Chief Medical Officer holding 71,530 shares of RARE after the transaction. In another insider transaction, Crombez Eric sold 242 shares at $35.11 per share on Apr 21 ’25. Company shares held by the EVP and Chief Medical Officer now total 71,680.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, RARE has a high of $60.37 and a low of $25.81.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $1.54, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.85.
